We aim to develop novel treatments or personalised treatment approaches for complex, immune-mediated diseases
With a greying population in the Netherlands, the health burden of complex, immune mediated diseases of the gastro-intestinal tract is rapidly increasing. We aim to uncover how the genetic or gut microbial make-up or the environment of an individual contributes to the development of complex, immune-mediated diseases. This knowledge enables the pinpointing of novel targets for personalised prevention and treatment using either existing approved drugs (drug repurposing) or innovative (e.g. microbiome directed) treatment protocols.
We focus on the mechanisms of complex, immune-mediated diseases of the gastro-intestinal tract, but similar or identical mechanisms and factors (both genetical, microbial and environmental) are involved in other complex diseases such as type 1 diabetes (T1D), rheumatoid arthritis (RA), multiple sclerosis (MS), and others. Because of this, our research results will contribute to the understanding and treatment of complex diseases in a broader sense.
- We generated public awareness on the influence of non-antibiotic drugs on the gut microbiome (specifically proton pump inhibitors, which are taken by > 2 million people in the Netherlands).
- We published a cahier on Organs-on-chip
- We established large-scale public-private collaborations (e.g. with Takeda, DSM, Winclove)